Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Condition(s):Safety Issues; Efficacy; MTDLast Updated:November 21, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Safety Issues; Efficacy; MTDLast Updated:November 21, 2023Recruiting
Condition(s):Nasopharyngeal Carcinoma; SintilimabLast Updated:February 1, 2023Recruiting
Condition(s):Advanced Solid TumoursLast Updated:March 19, 2024Recruiting
Condition(s):Renal Cell Carcinoma; FH-deficient; SintilimabLast Updated:May 12, 2020Unknown status
Condition(s):CholangiocarcinomaLast Updated:December 29, 2022Recruiting
Condition(s):Diffuse Large B-Cell Lymphoma; Sintilimab; TP53 MutationLast Updated:December 11, 2019Unknown status
Condition(s):Sintilimab and Anlotinib in Combination With ChemotherapyLast Updated:August 29, 2023Completed
Condition(s):Sintilimab, Cetuximab, Regorafenib,Combine,mCRCLast Updated:February 14, 2023Recruiting
Condition(s):Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-small-cell Lung CancerLast Updated:May 1, 2020Unknown status
Condition(s):Pancreatic Cancer, Stage IB; Pancreatic Cancer, Stage IIA; Pancreatic Cancer, Stage IIB; Pancreatic Cancer Stage IIILast Updated:June 27, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.